Figure 5 | Leukemia

Figure 5

From: Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib

Figure 5

Dynamics of RIPA measurements after pause/discontinuation of ibrutinib therapy in CLL patients. (a) Platelet function partly recovered (median 12 vs 54 U, P=0.004) after pause/discontinuation of ibrutinib therapy. The median time between measurements was 18 days in 9 patients. (b) In five patients, RIPA was measured in shorter intervals after discontinuation. The threshold of 36 U was reached within 7 days by 4/5 patients.

Back to article page